Sepsis is a lethal disease in Australia and globally. There has never been a greater need to develop a test that can provide a rapid diagnosis.
One of the leading causes of mortality and morbidity globally, malaria was responsible for around 438,000 deaths and 214 million clinical cases in 2015. An estimated 3.2 billion people are at risk of the disease, with young children and pregnant women most affected.
A two-way pipeline will be created where our research discoveries can be tested in the field, and field programs inform discovery research through our long-standing connections with vulnerable target populations, especially in Papua New Guinea and Myanmar.
Through this program, Burnet will contribute to:
reaching the WHO elimination targets of a 90 percent reduction in malaria incidence and mortality through an active program of basic, discovery and translational research and in-field education, prevention and treatment programs.
supporting country programs in our region that assist WHO in reaching targets of elimination in at least 35 countries by 2030.
Deputy Director (People); Head of Malaria Research: Immunity, Vaccines and New Therapies Laboratory; Adjunct Professor Monash University